Competition Equity Pricing Seed Funding 
Both Sides of the Table
SEPTEMBER 23, 2010
They might not actively “collude&# and say “let’s collectively keep the price down&# but in the resulting discussion pricing information will flow – whether intentional or not. They’re not in search of price fixing or collusion, they’re in search of diligence information about the company.
TechCrunch LA
SEPTEMBER 18, 2019
AOL co-founder and former chief executive officer Steve Case’s venture capital fund, Revolution , deploys capital to companies “outside of the hotbeds.” Sieg recently joined us on Equity , TechCrunch’s venture capital podcast, to explain the firm’s “rise of the rest” philosophy. Revolution co-founder Tige Savage.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Both Sides of the Table
JULY 15, 2010
Heck, stick around and watch me discuss the seed funding debate that is going on right now and what is happening in the VC industry overall. Convertible debt is a loan to the company that doesn’t typically get paid back but rather “converts&# into equity when you raise a larger round at a later date.
Both Sides of the Table
SEPTEMBER 10, 2021
On the other hand, the biggest winners will turn out to be much larger than the prices people paid for them and this will happen faster than at any time in human history. And as a result of this there are now very robust secondary markets where founders and seed-funds alike are selling down their ownership long before an ultimate exit.
Both Sides of the Table
JULY 16, 2010
So even within the “alternative class&# our LPs are looking at other asset investment choices such as distressed buyout funds, private equity or hedge funds. This means that some funds will disappea r – Returns are not even. The top quartile funds have performed well. VC will shrink. Oh yes it will.
Both Sides of the Table
MAY 23, 2010
a loan) that is later converted to equity at the time of the next financing. If no financing happened then this “note&# may not be converted and thus would be senior to the equity of the company in the case of a bankruptcy or asset sale. Maybe the market views this as not worth the price you paid?
Xconomy
JUNE 3, 2016
The only remaining daptomycin patent will expire in June, clearing the way for generic competition years earlier than expected. A company official told Xconomy the drug would be priced in line with standard of care enzyme replacement therapy, which costs around $300,000 per patient, per year.
Expert insights. Personalized for you.
292 
Let's personalize your content